Current options for the management of multidrug-resistant tuberculosis (review)

Jean-Pierre Zellweger


Multidrug-resistant tuberculosis (MDR-TB) is a major threat to tuberculosis control in many parts of the world. The current options for managing this form of the disease are an optimal use of existing drugs, use of re-purposed or new drugs and some non-antibiotic therapeutic options. The prevention of the creation and transmission of drug-resistant strains will be crucial for the global management of tuberculosis in the future.

Полный текст:

PDF (English)


World Health Organization. The global plan to stop TB 2011-2015. Geneva: World Health Organization, 2011.

World Health Organization. Towards tuberculosis elimination: an action framework for low-incidence countries. WHO, 2014. Report No.: WHO/HTM/TB/2014.13.

Wolinsky E.R.A., Steenken W.Jr. Drug-resistant tubercle bacilli in patients under treatment with streptomycin // Am. Rev. Tuberc. 1948. Vol. 58. Р. 335-343.

Werf van der M.J., Langendam M.W., Huitric E., Manissero D. Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis // Eur. Respir. J. 2012. Vol. 39. Р. 1511-1519.

Zhang Y., Yew W.W. Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015 // Int. J. Tuberc. Lung Dis. 2015. Vol. 19. Р. 1276-1289.

Pasipanodya J.G., McIlleron H., Burger A., Wash P.A., Smith P., Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes // J. Infect. Dis. 2013. Vol. 208. Р. 1464-1473.

Prideaux B., Via L.E., Zimmerman M.D. et al. The association between sterilizing activity and drug distribution into tuberculosis lesions // Nat. Med. 2015. Vol. 21. Р. 1223-1227.

World Health Organization. Global tuberculosis report 2016. Geneva: World Health Organization, 2016. Report No.: WHO/ HTM/TB/2016.13.

Ahuja S.D., Ashkin D., Avendano M. et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients // PLoS Medicine. 2012. Vol. 9. Р. e1001300.

Royce S., Falzon D., van Weezenbeek C. et al. Multidrug resistance in new tuberculosis patients: burden and implications // Int. J. Tuberc. Lung Dis. 2013. Vol. 17. Р. 511-513.

Yablonskiy P.K., Vizel A.A., Galkin V.B., Shulgina M.V. Tuberculosis in Russia. Its history and its status today // Am. J. Respir. Crit. Care Med. 2015. Vol. 191. Р. 372-376.

World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis. 2016 update. Geneva: World Health Organization, 2016. Report No.: WHO/HTM/ TB/2016.04.

Albert H., Nathavitharana R.R., Isaacs C., Pai M., Denkinger C.M., Boehme C.C. Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? // Eur. Respir. J. 2016. Vol. 48. Р. 516525.

Lange C., Abubakar I., Alffenaar J.W. et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement // Eur. Respir. J. 2014. Vol. 44. Р. 23-63.

Zhang Y., Yew W.W. Mechanisms of drug resistance in Mycobacterium tuberculosis // The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease 2009. Vol. 13. Р. 1320-1330.

Dominguez J., Boettger E.C., Cirillo D. et al. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus statement // Int. J. Tuberc. Lung Dis. 2016. Vol. 20. Р. 24-42.

Ziganshina L.E., Titarenko A.F., Davies G.R. Fluoroquinolones for treating tuberculosis (presumed drug-sensitive) // Cochrane Database Syst. Rev. 2013. CD004795.

Zignol M., Dean A.S., Alikhanova N. et al. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazi- namide and fluoroquinolones: results from a multicountry surveillance project // Lancet Infect. Dis. 2016.

Cox H., Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and metaanalysis // Int. J. Tuberc. Lung Dis. 2012. Vol. 16. Р. 447-454.

GopalM., PadayatchiN., Metcalfe J.Z., O'DonnellM.R. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis [Review article] // Int. J. Tuberc. Lung Dis. 2013. Vol. 17. Р. 1001-1007.

Jaganath D., Lamichhane G., Shah M. Carbapenems against Mycobacterium tuberculosis: a review of the evidence // Int. J. Tuberc. Lung Dis. 2016. Vol. 20. Р. 1436-1447.

Gunther G., Gomez G.B., Lange C., Rupert S., van Leth F. on behalf of the T. Availability, price and affordability of anti-tuberculosis drugs in Europe: A TBNET survey // Eur. Respir. J. 2014.

Van Deun A., Maug A.K., Salim M.A. et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis // Am. J. Respir Crit. Care Med. 2010. Vol. 182. Р. 684- 692.

Aung K.J., Van Deun A., Declercq E. et al. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients // Int. J. Tuberc. Lung Dis. 2014. Vol. 18. Р. 1180-1187.

Piubello A., Harouna S.H., Souleymane M.B. et al. High cure rate with standardised short-course multidrug-resistant tu

berculosis treatment in Niger: no relapses // Int. J. Tuberc. Lung Dis. 2014. Vol. 18. Р. 1188-1194.

Sotgiu G., Tiberi S., D'Ambrosio L. et al. Faster for less: the new «shorter» regimen for multidrug- resistant tuberculosis // Eur. Respir. J. 2016.

Altena van R., Akkerman O.W., Alffenaar J.C. et al. Shorter treatment for multidrug-resistant tuberculosis: the good, the bad and the ugly // Eur. Respir. J. 2016. Vol. 48. Р. 18001802.

World Health Organization. The use of bedaquiline in the treatment of multidrug- resistant tuberculosis. Interim policy guidance. Geneva, 2013.

World Health Organization. The use of delamanid in the treatment of multidrug- resistant tuberculosis. Interim policy guidance. Geneva, 2014.

Bloemberg G.V., Keller P.M., Stucki D. et al. Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis // N. Engl. J. Med. 2015. Vol. 373. Р. 1986-1988.

Tadolini M., Lingtsang R.D., Tiberi S. et al. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline // Eur. Respir. J. 2016. Vol. 48. Р. 935938.

Lachatre M., Rioux C., Le Du D. et al. Bedaquiline plus delamanid for XDR tuberculosis // Lancet Infect Dis. 2016. Vol. 16. Р. 294.

Bonnet M., Bastard M., du Cros P. et al. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study // Int. J. Tuberc. Lung Dis. 2016. Vol. 20 Р. 177-186.

Gopal P., Dick T. The new tuberculosis drug Perchlozone(R) shows cross-resistance with thiacetazone // Int. J. Antimi- crob Agents. 2015. Vol. 45. Р. 430-433.

Abdool Karim S.S., Naidoo K., Grobler A. et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy // N. Engl. J. Med. 2010. Vol. 362. Р. 697-706.

Middelkoop K., Bekker L.G., Myer L. et al. Antiretroviral program associated with reduction in untreated prevalent tuberculosis in a South African township // Am. J. Respir Crit Care Med. 2010. Vol. 182. Р. 1080-1085.

Abate G., Hoft D.F. Immunotherapy for tuberculosis: future prospects // Immunotargets Ther. 2016. Vol. 5. Р. 37-45.

Hofman S., Segers M.M., Ghimire S. et al. Emerging drugs and alternative possibilities in the treatment of tuberculosis // Expert Opin Emerg Drugs. 2016. Vol. 21. Р. 103-116.

Tameris M.D., Hatherill M., Landry B.S. et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial // Lancet. 2013. Vol. 381. Р. 1021-1028.

Wallis R.S. Reconsidering adjuvant immunotherapy for tuberculosis // Clin. Infect. Dis. 2005. Vol. 41. Р. 201-208.

Pham D.D., Fattal E., Tsapis N. Pulmonary drug delivery systems for tuberculosis treatment // Int. J. Pharm. 2015. Vol. 478. Р. 517-529.

Das S., Tucker I., Stewart P. Inhaled dry powder formulations for treating tuberculosis // Curr. Drug Deliv. 2015. Vol. 12. Р. 26-39.

Levin A., Sklyuev S., Felker I., Tceymach E., Krasnov D. Endobronchial valve treatment of destructive multidrug-resistant tuberculosis // Int. J. Tuberc. Lung Dis. 2016. Vol. 20. Р. 1539-1545.

Dara M., Sotgiu G., Zaleskis R., Migliori G.B. Untreatable tuberculosis: is surgery the answer? Eur. Respir J. 2015. Vol. 45. Р. 577-582.


  • На текущий момент ссылки отсутствуют.